Welcome to our dedicated page for Gilead Sciences SEC filings (Ticker: GILD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Gilead Sciences, Inc. (Nasdaq: GILD) is a Delaware‑incorporated biopharmaceutical company whose common stock is registered on The Nasdaq Global Select Market. As an SEC‑reporting issuer, Gilead files a range of regulatory documents that provide detailed insight into its financial condition, governance and material events. This page aggregates GILD’s SEC filings and pairs them with AI‑generated summaries to help readers understand the key points in complex disclosures.
For Gilead, Form 10‑K annual reports and Form 10‑Q quarterly reports are central sources of information on its HIV, viral hepatitis, COVID‑19, oncology and inflammation businesses, including segment discussions, risk factors and research and development spending. Form 8‑K current reports capture specific developments such as quarterly financial results, amendments to bylaws, executive leadership changes and significant agreements. Recent 8‑K filings, for example, have disclosed financial results for particular quarters, updates to the company’s bylaws governing director nominations and stockholder proposals, patent settlements related to Biktarvy, and changes in senior corporate affairs and legal roles.
Investors can also use this page to access proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports to track trades by directors and officers. Because Gilead is not classified as an emerging growth company, its filings follow the full disclosure requirements applicable to large, established issuers.
Stock Titan enhances GILD filings with AI‑powered explanations that highlight material items, translate technical accounting and legal language into plain terms, and surface topics such as governance changes, litigation updates or collaboration agreements. Real‑time ingestion from EDGAR means new Gilead filings appear quickly, while the AI layer helps readers focus on what changed, why it matters for the company’s HIV, antiviral and oncology franchises, and how it may affect shareholders.
Gilead Sciences, through its wholly owned subsidiary Ravens Sub, Inc., is offering to acquire Arcellx, Inc. by purchasing all outstanding common shares at
The Schedule TO states 58,672,448 shares were outstanding as of
Gilead Sciences Chief Financial Officer Andrew D. Dickinson acquired 11,090 shares of common stock through a grant/award on performance share units. These shares vested after both performance and service conditions were met, bringing his directly held total to 178,869 shares of Gilead common stock.
Mercier Johanna reported acquisition or exercise transactions in this Form 4 filing.
Gilead Sciences executive Johanna Mercier received 11,090 shares of common stock through the vesting of performance share award tranches. These shares relate to awards granted on March 10, 2025 that carried both performance- and service-vesting conditions. After this award, her directly held common stock totals 131,378 shares.
Gilead Sciences Chief Medical Officer Dietmar Berger acquired 8,530 shares of common stock at no cost through a grant/award transaction. These shares relate to specific tranches of performance share awards originally granted on March 10, 2025.
The performance-vesting requirement for these tranches was satisfied on February 27, 2026, when the Compensation and Talent Committee certified that the performance goals were met. Following this award, Berger directly holds a total of 17,912 Gilead common shares.
Gilead Sciences executive reports stock award vesting. EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M acquired 470 shares of Gilead common stock on the reported date at a stated price of $0.00 per share, increasing directly held common stock to 4,414 shares.
The shares relate to specific tranches of performance share awards originally granted on March 10, 2025. These tranches were subject to both performance-vesting and service-vesting conditions, with the performance goals certified as attained by the Compensation and Talent Committee on the reported vesting date.
Gilead Sciences Chairman & CEO Daniel O'Day reported both an equity award and stock sales. He acquired 38,396 shares of common stock at
On the same date, he sold a total of 10,000 common shares in open-market transactions at prices ranging from about
Daniel O'Day reports proposed sales of GILD common stock under Form 144. The filing lists recent transactions including a sale of
Gilead Sciences is a large biopharmaceutical company focused on HIV, liver disease, COVID-19 and oncology, with a global presence in more than 35 countries. Its medicines include HIV regimens like Biktarvy and Descovy, liver treatments such as Epclusa and Vemlidy, COVID-19 therapy Veklury, and cell therapies Yescarta and Tecartus.
The company highlights a broad late‑stage pipeline in virology and oncology, including lenacapavir for HIV prevention, bulevirtide for hepatitis delta, and multiple CAR T and antibody‑drug conjugate programs. It emphasizes extensive patent protection, with key products such as Biktarvy and Veklury covered into the 2030s, and notes growing pricing and reimbursement pressures from U.S. policy changes like the Inflation Reduction Act, Medicaid and 340B rules, and international cost controls.
Gilead also describes significant manufacturing infrastructure in the U.S., Europe and Canada, reliance on contract manufacturers, and a workforce of about 17,000 employees. It stresses human capital, ESG priorities and detailed risk factors spanning competition, product demand volatility, regulatory change, climate rules and complex U.S. drug‑pricing reforms.
Gilead Sciences, through wholly owned Purchaser Ravens Sub, Inc., announced a proposed acquisition of Arcellx, Inc. The offer contemplates
The tender offer has not commenced; the communication is a preliminary solicitation and states that final tender offer materials, including a Schedule TO and Arcellx’s Schedule 14D-9, will be filed with the SEC when the offer begins.
Gilead Sciences entered into a merger agreement to acquire Arcellx through a tender offer for
The CVR entitles holders to